Wockhardt Aims To Regain Rs 5,000-Crore Revenue In Three Years, Says Chairperson Khorakiwala

Wockhardt Ltd. expects to regain its revenue levels of around Rs 5,000 crore, last seen in 2014–15, within the next three years, according to Chairperson Habil Khorakiwala.

Khorakiwala projected the top line to grow from the current Rs 3,000 crore to over Rs 5,000 crore in the next three years.

"I think it gives us three years from now, maybe we should be there basically," he told NDTV Profit in a conversation on Tuesday when asked about Wockhardt returning to revenue levels of around Rs 5,000 crore, similar to what it achieved nearly a decade ago.

The margin, currently averaging 12–13%, is also expected to improve significantly due to the introduction of new high-margin molecules and an expanding portfolio, the chairperson added.

In FY25, the company’s revenue stood at Rs 3,012 crore, compared to Rs 2,798 crore in FY24.

Asked if the margin could be upwards of 20%, Khorakiwala did not confirm a figure, but expressed optimism. "Margin will certainly improve because of the new molecule. The large-margin initial portfolio will also increase significantly, which will contribute to higher margins," he said.

On the recent impressive Q4 FY25 results, he attributed the strong Ebitda performance to significant cost reductions across the organisation.

"We have completed three clinical trials and plan to file with the US FDA sometime in August. So collectively, I believe there will be a lot of upside from our new drugs. Some benefits will come in the current year, but the most dramatic changes are expected in FY 26–27," he added.

Khorakiwala acknowledged that launching new products involves upfront expenses, alongside accelerating their robust research portfolio, which will require additional funding. To support both debt reduction and increased R&D spend, Wockhardt plans to raise funds through a combination of debt and equity.

"When you launch a product, there are upfront expenses involved in marketing and building up the business. Additionally, we have a robust research portfolio, and we want to accelerate that process as well. So, funding will be required, and we will try to raise funds through a combination of debt and equity," he explained.

According to Khorakiwala, this fundraising could happen within the next six to 12 months.